In the last 10 years, the clinical application of these ICIs, particularly those targeting the PD‐1/PD‐L1 axis, has fundamentally transformed the approach to treating advanced cancers, particularly solid tumors [7, 8, 9]. This evidence concerns the gene PDCD1 and cancer.